A phase III, randomized, open-label, study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy (NHT) in patients (pts) with metastatic, castration-resistant prostate cancer (mCRPC).

被引：6

作者：

Agarwal, Neeraj ^{[1
]}

Azad, Arun ^{[2
]}

Carles, Joan ^{[3
]}

Chowdhury, Simon ^{[4
,5
,6
,7
]}

McGregor, Bradley Alexander ^{[8
]}

Merseburger, Axel Stuart ^{[9
]}

Oudard, Stephane ^{[10
]}

Saad, Fred ^{[11
]}

Soares, Andrey ^{[12
]}

Panneerselvam, Ashok ^{[13
]}

Wang Fong ^{[13
]}

Pal, Sumanta K. ^{[14
]}

机构：

[1] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA

[2] Peter MacCallum Canc Ctr, Sydney, NSW, Australia

[3] Vall dHebron Univ Hosp, Barcelona, Spain

[4] Guys Hosp, London, England

[5] Kings Hosp, London, England

[6] St Thomas Hosp, London, England

[7] Sarah Cannon Res Inst, London, England

[8] Dana Farber Canc Inst, Boston, MA 02115 USA

[9] Univ Hosp Schleswig Holstein, Campus Luebeck, Lubeck, Germany

[10] Univ Paris, Georges Pompidou Hosp, Paris, France

[11] Ctr Hosp Univ Montreal, Montreal, PQ, Canada

[12] Hosp Israelita Albert Einstein, Sao Paulo, Brazil

[13] Exelixis Inc, Alameda, CA USA

[14] City Hope Comprehens Canc Ctr, Dept Med Oncol & Therapeut, Duarte, CA USA

来源：

关键词：

D O I：

10.1200/JCO.2021.39.6_suppl.TPS190

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS190

引用

页数：3